An authors’ error occurred in this paper by Dr Alagiakrishnan and others (2006;82:101–5). The competing interests statements were not included in the paper. The statements are printed below.

Peter N McCracken: in the past three years I have received grant research support from Pfizer, Eisai, Sanofi-aventis, Lundbeck Canada, Servier Canada, Janssen-Ortho, and Neurochem Inc, Syreon Corporation, and Wyeth. I have served as a consultant for Pfizer, Eisai, Novartis, Lundbeck Canada, and Janssen Ortho. I have been on the Speaker’s Bureau or served in CME programmes with Pfizer, Eisai, Novartis, Lundbeck, and Janssen Ortho. I am not a shareholder in these firms and receive no other financial or material support.

Howard Feldman: in the past three years, I have/have had a financial interest/arrangement or affiliation with the following organisations: grant/research support (external): Pfizer, Eisai, Janssen, Lilly, Astra Zeneca, Sanofi Synthelabo, Glaxo Smith Kline. Consultant: Pfizer, Eisai, Novartis, Janssen, Servier, Sanofi Synthelabo, Glaxo Smith Kline, Myriad, Targacept, Lundbeck, Forest, Axonyx. Speakers’ Bureau, or CME programmes: Pfizer, Eisai, Janssen, Novartis, Forest. For this specific article I have had financial arrangements with Pfizer, Eisai, Novartis, and Janssen as listed above. They are the manufacturers of the acetylcholinesterase inhibitors. Pfizer is also the manufacturer of atorvastatin, a statin that is being investigated in Alzheimer’s disease and for which I have been a consultant.

Kannayiram Alagiakrishnan: in the past three years I have received research support from Janssen-Ortho.